An insider from MRNA, Tal Zvi Zaks has sold close to 1,199 shares of the company’s stock in a Monday transaction that took place on the 22nd of March. The average price of the stock was $144.82, which was sold at a total package of $173,639.18. After the sale, the insider has control over 1,199 shares of the company. The document is securely available with the SEC.
The Quarterly Estimate Of MRNA
The stocks of MRNA traded on Tuesday, at $7.83. The moving average price of the company over a period of 50 days has been set at $157.13, while the moving average price of the company over a period of 200 days is $114.63. The year low of the company is $24.36, while the year high of the company has been set at $189.26. The market cap of the firm has been fixed at $55.18 billion, with a -89.88 PE ratio, along with a 1.73 beta. The debt-to-equity ratio of the company has been fixed at 0.04, with a 2.43 current ratio.
The MRNA stocks previously issued their results of quarterly earnings on the 25th of February. The EPS reported by the company for the quarter was $0.69, which missed out on the consensus estimate set at $0.25. The revenue earned by the company over the quarter was $570.80 million, which was more than the consensus estimate of $279.41 million. The net margin of the company was at a negative 242.73%, while the company also had a 28.11% negative return on its equity.
There have been quite a few research equities that have commented on the stocks of MRNA. The Goldman Sachs Group has already reaffirmed a rating of buy along with a price target of $139 in an 11th December price report. Argus has also increased the price target of the company from a sum of $88 to $200, along with a rating of buy in a 1st December research report.
Chardan Capital has also increased the price target of the company from $107 to $182, with a rating of buy that went with an 8th March research report. In the end, Piper Sandler decided to put up a rating of overweight with a price target of $208 in a Monday research note.
Three of the research analysts covering the stocks gave it a rating of sell, while seven of them have given it a rating of hold. Currently, the company enjoys a hold rating with a $150.66 price target.
